Wednesday 6-18-2014 Intellipharmaceutics International Inc (IPCI) $IPCI opened at 3.75 hitting the high price of 3.79 and a day low of 3.70 with a total volume of 125,967. IPCI had a previous close of 3.77 and has been seeing an average volume of 113,615.
Overall Average: 24% Sell
Recent stock forum discussions about IPCI http://investorshangout.com/search?q=IPCI&...mp;yt0=Go!
Intellipharmaceutics files up to USD100m preliminary base shelf prospectus and shelf registration statement
M2 - Wed May 21, 6:34AM CDT
Pharmaceutical company Intellipharmaceutics International (TSX:I) declared on Tuesday that it has filed a preliminary short form base shelf prospectus with securities regulatory authorities in each of the provinces and territories of Canada, except Quebec, and filed a registration statement with the US Securities and Exchange Commission on Form F-3. (full story)
Intellipharmaceutics Files Preliminary Base Shelf Prospectus and Shelf Registration Statement
GlobeNewswire - Tue May 20, 4:45PM CDT
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has filed a preliminary short form base shelf prospectus with securities regulatory authorities in each of the provinces and territories of Canada, except Quebec, and filed a registration statement with the United States Securities and Exchange Commission on Form F-3. Once the shelf prospectus is cleared and the shelf registration statement becomes effective, these filings would, subject to securities regulatory requirements and limitations, provide for the potential offering of up to an aggregate of US$100 million of the Company's common shares, preference shares, warrants, subscription receipts and units, or any combination thereof, from time to time in one or more offerings. This shelf prospectus is intended to give Intellipharmaceutics the flexibility to take advantage of financing opportunities when, and if, market conditions are favorable to the Company. The specific terms of such future offerings, if any, would be established, subject to the approval of the Company's Board of Directors, at the time of such offering and will be described in detail in a prospectus supplement filed at the time of any such offering. (full story)
Pharma Stocks Technical Briefing -- Research on Forest Laboratories, Valeant Pharma, IntelliPharmaCeutics Intl., and Acura Pharma
PR Newswire - Thu May 08, 7:09AM CDT
On Wednesday, May 7, 2014, the NASDAQ Composite ended at 4,067.67, down 0.32%, the Dow Jones Industrial Average advanced 0.72%, to finish the day at 16,518.54, and the S&P 500 closed at 1,878.21, up 0.56%. During the session, eight out of ten sectors ended on a positive note. The S&P 500 Health Care Sector Index ended the day at 668.01, up 0.23%, with the index advancing 2.50% in the previous three months. Investor-Edge has initiated coverage on the following equities: Forest Laboratories Inc. (NYSE: FRX), Valeant Pharmaceuticals International Inc. (NYSE: VRX), IntelliPharmaCeutics International Inc. (NASDAQ: IPCI) and Acura Pharmaceuticals Inc (NASDAQ: ACUR). Free technical research on FRX, VRX, IPCI and ACUR can be downloaded upon signing up at: (full story)
Flamel Technologies SA (FLML) Soars: Stock Up 6.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 8:39AM CDT
Flamel Technologies SA was a big mover last session, as its shares rose nearly 7% on the day. (full story)
Tetraphase Slumps: TTPH Falls 10.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 7:49AM CDT
Tetraphase Pharmaceuticals saw a big move last session, as the company’s shares fell by over 10% on the day (full story)
Intellipharmaceutics achieves net income of USD2.2m in Q1 2014
M2 - Tue Apr 15, 4:23AM CDT
Pharmaceutical company Intellipharmaceutics International (NasdaqCM:IPCI) (TSX:I) on Monday disclosed its net income of USD2.2m (USD0.09 per diluted common share) for the three months ended 28 February 2014. (full story)
Intellipharmaceutics Announces First Quarter 2014 Results
GlobeNewswire - Mon Apr 14, 6:01AM CDT
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three months ended February 28, 2014. All dollar amounts referenced herein are in United States dollars unless otherwise noted. (full story)
Flamel Technologies (FLML) Jumps: Stock Adds 9.8% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 7:51AM CDT
Flamel Technologies SA was a big mover last session, as its shares rose nearly 10% on the day. (full story)
Reviewing the Top Health Care Equities -- Research on IntelliPharmaCeutics, Delcath Systems, Valeant Pharma and Alkermes
PR Newswire - Fri Mar 21, 4:39PM CDT
On Thursday, March 20, 2014, the NASDAQ Composite ended at 4,319.29, up 0.27%, the Dow Jones Industrial Average gained 0.67% to reach 16,331.05, and the S&P 500 closed at 1,872.01, up 0.60%. The gains were broad based as nine of ten sectors finished higher. The S&P 500 Health Care Sector Index finished the day 0.02% lower at 686.29, whereas, the index has advanced 0.77% in the last one month. Investor-Edge has initiated coverage on the following equities: IntelliPharmaCeutics International Inc. (NASDAQ: IPCI), Delcath Systems Inc. (NASDAQ: DCTH), Valeant Pharmaceuticals International Inc. (NYSE: VRX) and Alkermes PLC (NASDAQ: ALKS). Free technical research on IPCI, DCTH, VRX and ALKS can be downloaded upon signing up at: (full story)
IntelliPharmaCeutics International (IPCI) Soars: Stock Rises 9.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 7:51AM CDT
IntelliPharmaCeutics International Inc. was a big mover last session, as its shares rose over 9% on the day. (full story)
Can the Rally in IntelliPharmaCeutics (IPCI) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 6:44AM CDT
Can the Rally in IntelliPharmaCeutics (IPCI) Shares Continue? (full story)
4 Stocks Under to Trade for Breakouts
at The Street - Fri Mar 21, 5:00AM CDT
These under-$10 stocks are within range of triggering breakout trades. (full story)
Intellipharmaceutics -- Amended Form of Proxy for Shareholders Meeting to be Held on March 27, 2014
GlobeNewswire - Wed Mar 19, 4:00PM CDT
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has sent to registered shareholders an amended form of proxy for voting at its annual and special shareholders meeting to be held on March 27, 2014 (the "Meeting"
. (full story)
Correction - Mackie Research Capital Initiates Coverage on Intellipharmaceutics Intl (NASDAQ:IPCI) (TSX:I) with a Speculative Buy Recommendation - Video Research Alert on InvestmentPitch.com
Thomson Reuters ONE - Mon Mar 17, 9:59AM CDT
Vancouver, BC, March 17, 2014 - Investment firm Mackie Research has initiated coverage on Intellipharmaceutics International, (NASDAQ:IPCI) (TSX:I). Analyst Andre Uddin gives the company a speculative buy recommendation and 12-month target of US$11.00, a premium of 140% to the $4.58 price on March 12th, the day the report was issued. (full story)
Jennings Capital Initiates Coverage on Intellipharmaceutics Intl (NASDAQ:IPCI) (TSX:I) with a Speculative Buy Recommendation - Video Research Alert on InvestmentPitch.com
Thomson Reuters ONE - Fri Mar 14, 5:22PM CDT
Vancouver, BC, March 14, 2014 - Investment firm Mackie Research has initiated coverage on Intellipharmaceutics International, (NASDAQ:IPCI) (TSX:I). Analyst Andre Uddin gives the company a speculative buy recommendation and 12-month target of US$11.00, a premium of 140% to the $4.58 price on March 12th, the day the report was issued. (full story)
Approvals, Clinical Trial Results, Stock Summaries, Data Publication and Conference Participation - Analyst Notes on Northwest, La Jolla Pharma, Merrimack Pharma, Rosetta, and IntelliPharmaCeutics
PR Newswire - Thu Mar 13, 7:20AM CDT
Today, Analysts Review released its analysts' notes regarding Northwest Biotherapeutics, Inc. (NASDAQ: NWBO), La Jolla Pharmaceutical Co. (NASDAQ: LJPC), Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK), Rosetta Genomics, Ltd. (NASDAQ: ROSG), and IntelliPharmaCeutics International Inc. (NASDAQ: IPCI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register (full story)
IntelliPharmaCeutics (IPCI) Jumps: Stock Up 8.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 7:51AM CDT
IntelliPharmaCeutics International Inc. was a big mover last session, as its shares rose nearly 9% on the day. (full story)
5 Stocks Ready for Breakouts
at The Street - Fri Mar 07, 1:19PM CST
These stocks look poised to break out and trade higher from current levels. (full story)
Intellipharmaceutics to Present at Two Upcoming Investor Conferences
GlobeNewswire - Tue Mar 04, 4:00PM CST
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, announced today that the Company is scheduled to present at the following two upcoming conferences. (full story)
Intellipharmaceutics posts higher net loss in 2013
M2 - Wed Feb 19, 6:11AM CST
Canadian pharmaceutical company Intellipharmaceutics International Inc (NasdaqCM:IPCI) (TSX:I) stated on Tuesday a net loss of USD11.5m (USD0.58 per common share) for the year ended 30 November 2013. (full story)
Overall Average: 24% Sell
Recent stock forum discussions about IPCI http://investorshangout.com/search?q=IPCI&...mp;yt0=Go!
Intellipharmaceutics files up to USD100m preliminary base shelf prospectus and shelf registration statement
M2 - Wed May 21, 6:34AM CDT
Pharmaceutical company Intellipharmaceutics International (TSX:I) declared on Tuesday that it has filed a preliminary short form base shelf prospectus with securities regulatory authorities in each of the provinces and territories of Canada, except Quebec, and filed a registration statement with the US Securities and Exchange Commission on Form F-3. (full story)
Intellipharmaceutics Files Preliminary Base Shelf Prospectus and Shelf Registration Statement
GlobeNewswire - Tue May 20, 4:45PM CDT
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has filed a preliminary short form base shelf prospectus with securities regulatory authorities in each of the provinces and territories of Canada, except Quebec, and filed a registration statement with the United States Securities and Exchange Commission on Form F-3. Once the shelf prospectus is cleared and the shelf registration statement becomes effective, these filings would, subject to securities regulatory requirements and limitations, provide for the potential offering of up to an aggregate of US$100 million of the Company's common shares, preference shares, warrants, subscription receipts and units, or any combination thereof, from time to time in one or more offerings. This shelf prospectus is intended to give Intellipharmaceutics the flexibility to take advantage of financing opportunities when, and if, market conditions are favorable to the Company. The specific terms of such future offerings, if any, would be established, subject to the approval of the Company's Board of Directors, at the time of such offering and will be described in detail in a prospectus supplement filed at the time of any such offering. (full story)
Pharma Stocks Technical Briefing -- Research on Forest Laboratories, Valeant Pharma, IntelliPharmaCeutics Intl., and Acura Pharma
PR Newswire - Thu May 08, 7:09AM CDT
On Wednesday, May 7, 2014, the NASDAQ Composite ended at 4,067.67, down 0.32%, the Dow Jones Industrial Average advanced 0.72%, to finish the day at 16,518.54, and the S&P 500 closed at 1,878.21, up 0.56%. During the session, eight out of ten sectors ended on a positive note. The S&P 500 Health Care Sector Index ended the day at 668.01, up 0.23%, with the index advancing 2.50% in the previous three months. Investor-Edge has initiated coverage on the following equities: Forest Laboratories Inc. (NYSE: FRX), Valeant Pharmaceuticals International Inc. (NYSE: VRX), IntelliPharmaCeutics International Inc. (NASDAQ: IPCI) and Acura Pharmaceuticals Inc (NASDAQ: ACUR). Free technical research on FRX, VRX, IPCI and ACUR can be downloaded upon signing up at: (full story)
Flamel Technologies SA (FLML) Soars: Stock Up 6.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 8:39AM CDT
Flamel Technologies SA was a big mover last session, as its shares rose nearly 7% on the day. (full story)
Tetraphase Slumps: TTPH Falls 10.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 7:49AM CDT
Tetraphase Pharmaceuticals saw a big move last session, as the company’s shares fell by over 10% on the day (full story)
Intellipharmaceutics achieves net income of USD2.2m in Q1 2014
M2 - Tue Apr 15, 4:23AM CDT
Pharmaceutical company Intellipharmaceutics International (NasdaqCM:IPCI) (TSX:I) on Monday disclosed its net income of USD2.2m (USD0.09 per diluted common share) for the three months ended 28 February 2014. (full story)
Intellipharmaceutics Announces First Quarter 2014 Results
GlobeNewswire - Mon Apr 14, 6:01AM CDT
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three months ended February 28, 2014. All dollar amounts referenced herein are in United States dollars unless otherwise noted. (full story)
Flamel Technologies (FLML) Jumps: Stock Adds 9.8% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 7:51AM CDT
Flamel Technologies SA was a big mover last session, as its shares rose nearly 10% on the day. (full story)
Reviewing the Top Health Care Equities -- Research on IntelliPharmaCeutics, Delcath Systems, Valeant Pharma and Alkermes
PR Newswire - Fri Mar 21, 4:39PM CDT
On Thursday, March 20, 2014, the NASDAQ Composite ended at 4,319.29, up 0.27%, the Dow Jones Industrial Average gained 0.67% to reach 16,331.05, and the S&P 500 closed at 1,872.01, up 0.60%. The gains were broad based as nine of ten sectors finished higher. The S&P 500 Health Care Sector Index finished the day 0.02% lower at 686.29, whereas, the index has advanced 0.77% in the last one month. Investor-Edge has initiated coverage on the following equities: IntelliPharmaCeutics International Inc. (NASDAQ: IPCI), Delcath Systems Inc. (NASDAQ: DCTH), Valeant Pharmaceuticals International Inc. (NYSE: VRX) and Alkermes PLC (NASDAQ: ALKS). Free technical research on IPCI, DCTH, VRX and ALKS can be downloaded upon signing up at: (full story)
IntelliPharmaCeutics International (IPCI) Soars: Stock Rises 9.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 7:51AM CDT
IntelliPharmaCeutics International Inc. was a big mover last session, as its shares rose over 9% on the day. (full story)
Can the Rally in IntelliPharmaCeutics (IPCI) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 6:44AM CDT
Can the Rally in IntelliPharmaCeutics (IPCI) Shares Continue? (full story)
4 Stocks Under to Trade for Breakouts
at The Street - Fri Mar 21, 5:00AM CDT
These under-$10 stocks are within range of triggering breakout trades. (full story)
Intellipharmaceutics -- Amended Form of Proxy for Shareholders Meeting to be Held on March 27, 2014
GlobeNewswire - Wed Mar 19, 4:00PM CDT
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has sent to registered shareholders an amended form of proxy for voting at its annual and special shareholders meeting to be held on March 27, 2014 (the "Meeting"
. (full story) Correction - Mackie Research Capital Initiates Coverage on Intellipharmaceutics Intl (NASDAQ:IPCI) (TSX:I) with a Speculative Buy Recommendation - Video Research Alert on InvestmentPitch.com
Thomson Reuters ONE - Mon Mar 17, 9:59AM CDT
Vancouver, BC, March 17, 2014 - Investment firm Mackie Research has initiated coverage on Intellipharmaceutics International, (NASDAQ:IPCI) (TSX:I). Analyst Andre Uddin gives the company a speculative buy recommendation and 12-month target of US$11.00, a premium of 140% to the $4.58 price on March 12th, the day the report was issued. (full story)
Jennings Capital Initiates Coverage on Intellipharmaceutics Intl (NASDAQ:IPCI) (TSX:I) with a Speculative Buy Recommendation - Video Research Alert on InvestmentPitch.com
Thomson Reuters ONE - Fri Mar 14, 5:22PM CDT
Vancouver, BC, March 14, 2014 - Investment firm Mackie Research has initiated coverage on Intellipharmaceutics International, (NASDAQ:IPCI) (TSX:I). Analyst Andre Uddin gives the company a speculative buy recommendation and 12-month target of US$11.00, a premium of 140% to the $4.58 price on March 12th, the day the report was issued. (full story)
Approvals, Clinical Trial Results, Stock Summaries, Data Publication and Conference Participation - Analyst Notes on Northwest, La Jolla Pharma, Merrimack Pharma, Rosetta, and IntelliPharmaCeutics
PR Newswire - Thu Mar 13, 7:20AM CDT
Today, Analysts Review released its analysts' notes regarding Northwest Biotherapeutics, Inc. (NASDAQ: NWBO), La Jolla Pharmaceutical Co. (NASDAQ: LJPC), Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK), Rosetta Genomics, Ltd. (NASDAQ: ROSG), and IntelliPharmaCeutics International Inc. (NASDAQ: IPCI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register (full story)
IntelliPharmaCeutics (IPCI) Jumps: Stock Up 8.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 7:51AM CDT
IntelliPharmaCeutics International Inc. was a big mover last session, as its shares rose nearly 9% on the day. (full story)
5 Stocks Ready for Breakouts
at The Street - Fri Mar 07, 1:19PM CST
These stocks look poised to break out and trade higher from current levels. (full story)
Intellipharmaceutics to Present at Two Upcoming Investor Conferences
GlobeNewswire - Tue Mar 04, 4:00PM CST
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, announced today that the Company is scheduled to present at the following two upcoming conferences. (full story)
Intellipharmaceutics posts higher net loss in 2013
M2 - Wed Feb 19, 6:11AM CST
Canadian pharmaceutical company Intellipharmaceutics International Inc (NasdaqCM:IPCI) (TSX:I) stated on Tuesday a net loss of USD11.5m (USD0.58 per common share) for the year ended 30 November 2013. (full story)
